Skip to main content

stock analysis

15 articles found

YUM: Franchise Empire Breaks to New 52-Week Highs

Yum! Brands (NYSE: YUM) has done what few mega-cap restaurant stocks manage in a choppy market — it has broken to new 52-week highs. The stock closed at $168.16 on February 28, 2026, surpassing its prior peak of $165.32 and setting a fresh 52-week high of $169.39. That represents a 22.5% rally from its 52-week low of $137.33 and places the parent company of KFC, Taco Bell, Pizza Hut, and The Habit Burger Grill at a market capitalization of $46.7 billion. The breakout comes on the back of a strong Q4 2025 earnings report — the best quarter of the fiscal year — featuring $2.514 billion in revenue, a 21.3% net margin, and diluted EPS of $1.92. Full-year 2025 revenue came in at approximately $8.21 billion with EPS of $5.56, confirming the thesis that YUM's asset-light franchise model generates steadily compounding cash flows regardless of macroeconomic noise. But at 30.3x trailing earnings with negative book value and over $12 billion in long-term debt, the stock's breakout demands fresh scrutiny. Is the franchise royalty machine priced to perfection, or does the growth runway justify the premium?

YUMYum BrandsKFC

NVO: GLP-1 Giant Falls to 10x Earnings on Lilly Fears

Novo Nordisk shares have collapsed to $37.45, a 59% decline from their 52-week high of $91.90, after the company's next-generation obesity drug CagriSema delivered clinical trial results that trailed Eli Lilly's Zepbound. The February 27 selloff alone erased 21% of the stock's value in a single session, marking the most dramatic repudiation of a GLP-1 leader since the obesity drug revolution began. At 10.3 times trailing earnings, Novo Nordisk now trades at a valuation that would be cheap for a utility company — let alone a pharmaceutical giant that generated DKK 308 billion ($44 billion) in revenue last year with 81% gross margins. The market cap has contracted to $166.5 billion, roughly half of where it stood six months ago. The question facing investors is whether the CagriSema disappointment is a fundamental thesis-breaker or whether the market has overreacted. Novo Nordisk still dominates the GLP-1 market alongside Eli Lilly, with Wegovy and Ozempic generating massive cash flows. But with the company guiding for a 5–13% decline in 2026 sales due to U.S. price compression, the near-term outlook is genuinely challenging. For context on how NVO reached this point, see our [earlier analysis of the 50% price reduction](/articles/nvo-analysis-novo-nordisks-50-price-slash-creates-a-deep-value-puzzle-for-glp-1-investors) that preceded this latest crash.

NVONovo NordiskGLP-1

BRK-B: Berkshire Hathaway's Q4 Operating Earnings Drop 29%

Berkshire Hathaway reported its fourth-quarter 2025 results on Saturday, marking Warren Buffett's final quarter as CEO before handing the reins to longtime deputy Greg Abel. Operating earnings fell 29% to $10.2 billion from $14.56 billion in the year-earlier period, driven primarily by a sharp decline in insurance underwriting results. The stock trades at $505.22 per share, giving the conglomerate a $1.09 trillion market capitalisation. The headline earnings decline masks a more nuanced picture. Berkshire's cash pile stood at $373.3 billion at year-end, down just 2.1% from September's record, as Buffett continued his restrained approach to capital deployment in his final months. Abel, in his first annual shareholder letter, pledged to maintain Berkshire's "fortress-like" balance sheet while identifying Apple, American Express, Coca-Cola, and Moody's as effectively permanent holdings — signalling continuity rather than upheaval. For investors parsing the leadership transition, the Q4 numbers provide both a data point and a litmus test: can Abel maintain Berkshire's operating machine while eventually putting that $373 billion cash hoard to work in a way that moves the needle for a trillion-dollar enterprise?

BRK-BBerkshire HathawayGreg Abel

CAVA: CAVA Group's 20% Post-Earnings Rally Confronts a

CAVA Group (NYSE: CAVA) has surged roughly 20% over the past week following its Q4 2025 earnings report, pushing shares to $82.47 — nearly double the 52-week low of $43.41 set earlier in the year. The Mediterranean fast-casual chain has become one of the most closely watched growth stories in the restaurant sector, drawing inevitable comparisons to Chipotle's early-stage trajectory. But beneath the headline rally lies a more nuanced picture. Q4 same-restaurant sales growth decelerated to just 0.5%, a sharp slowdown from the high-single-digit pace investors had grown accustomed to. Revenue for the quarter came in at $275.0 million with a net loss of $0.18 per share, as the company invested heavily in new unit openings. Management guided for 3-5% same-restaurant sales growth in 2026 — well below the torrid pace that initially captivated Wall Street. With a market capitalization of $9.57 billion and a trailing P/E ratio of 72.3x, CAVA is priced for a growth story that hasn't fully materialized in the recent quarters. The question for investors: is the unit-expansion thesis enough to justify the premium, or has the market gotten ahead of itself?

CAVA GroupCAVAstock analysis

NFLX: Netflix's 25% Weekly Surge Signals a New Chapter

Netflix (NASDAQ: NFLX) has exploded 25% in a single week, surging to $96.24 per share on massive volume of 190.8 million shares — nearly four times its daily average of 47.8 million. The catalyst was Netflix's decision to walk away from its bid for Warner Bros. Discovery, allowing Paramount Skydance to close a $110 billion acquisition instead. The market's verdict was unambiguous: investors rewarded Netflix's capital discipline with a move that added roughly $80 billion in market capitalization. The rally brings Netflix's market cap to $407.8 billion and its shares within striking distance of the 50-day moving average of $86.30, though still well below the 200-day average of $110.22 and the 52-week high of $134.12. With full-year 2025 revenue of $45.2 billion and net income approaching $11 billion, the question facing investors is whether Netflix's decision to stay lean and organic represents genuine strategic wisdom — or a missed opportunity to consolidate a fragmenting industry.

NetflixNFLXstock analysis

BRK-B Analysis: Berkshire Hathaway's Q4 Earnings Preview

Berkshire Hathaway (BRK-B) trades at $504.09 per share with a market capitalization of $1.09 trillion as the company heads into its most anticipated earnings release in decades. The stock is up 1.2% over the past week, sitting 7% below its 52-week high of $542.07, with trailing twelve-month earnings of $31.25 per share producing a P/E ratio of 16.1x. Tomorrow — February 28, 2026 — Berkshire reports Q4 2025 results after market close. This is no ordinary earnings release. It marks the first report since Greg Abel officially succeeded Warren Buffett as CEO on January 1, 2026, and Abel is expected to use the occasion to lay out his thinking for a post-Buffett Berkshire. Reuters reports that Abel faces "numerous challenges as the successor to famed billionaire Warren Buffett" and will need to articulate his vision for the conglomerate's future direction. With a $382 billion cash and short-term investment pile, a $633 billion total investment portfolio, and a leadership transition that represents the most significant change in Berkshire's 60-year history, this earnings call will set the tone for the Abel era. Here's what investors need to know heading into the report.

Berkshire HathawayBRK-BWarren Buffett

NVO: Novo Nordisk's 50% Price Slash Creates a Deep-Value

Novo Nordisk (NVO) has gone from the world's most valuable healthcare company to a deep-value opportunity in the span of twelve months. Shares closed at $38.16 on February 25, 2026 — down 59% from their 52-week high of $93.80 and trading at just 10.5x trailing earnings. The Danish pharmaceutical giant hit a fresh 52-week low of $37.65 during today's session on volume 2.6 times the daily average, as investors digested the company's announcement that it will cut U.S. list prices on Ozempic and Wegovy by up to 50% starting in 2027. The price cuts represent a strategic pivot that could reshape the entire GLP-1 market. For years, Novo Nordisk and rival Eli Lilly have commanded premium pricing for their obesity and diabetes drugs — Ozempic and Wegovy carry U.S. list prices above $1,000 per month. By voluntarily halving prices, Novo is betting that volume gains from dramatically expanded insurance coverage and patient access will more than offset the per-unit revenue decline. It is a gamble that pits near-term margin compression against long-term market dominance. For investors, the question is straightforward: does a sub-11x P/E ratio adequately compensate for the margin headwinds ahead, or is the selloff a classic overreaction that creates a generational entry point into the world's dominant GLP-1 franchise? The answer lies in Novo's financial fundamentals, its competitive moat, and whether the company's massive manufacturing investments can deliver the scale needed to make lower prices profitable.

NVONovo NordiskOzempic

Deep Dive: What Is Return on Equity (ROE)

Return on equity is one of the most widely cited profitability metrics in investing — and for good reason. It answers a deceptively simple question: how effectively is a company turning shareholder capital into profit? A business that generates $20 million in net income on $100 million of shareholders' equity earns a 20% ROE, meaning every dollar of equity produces 20 cents of annual profit. That single number captures the intersection of pricing power, cost discipline, asset efficiency, and capital structure decisions. But ROE's simplicity can be misleading. Apple currently reports a trailing annualized ROE above 160%, while Tesla barely manages 4%. Does that make Apple forty times more effective at deploying capital? Not necessarily. Apple's aggressive share buyback program has compressed its equity base to roughly $57 billion despite earning over $90 billion annually — mathematically inflating ROE to eye-popping levels. Meanwhile, Tesla sits on a massive equity cushion with relatively thin margins. Understanding what drives ROE, and when it's telling the truth versus flattering the picture, separates informed investors from those chasing misleading numbers. This guide breaks down ROE from first principles: the formula, the DuPont decomposition that reveals its three hidden drivers, real cross-sector data from eight major companies, and practical frameworks for using ROE alongside its companion metric, return on assets (ROA). Whether you're screening stocks, comparing management teams, or evaluating whether a company's profitability is sustainable, ROE is a tool you'll reach for constantly — but only if you know how to read it properly.

return on equityROEDuPont analysis

Deep Dive: What Is CAGR (Compound Annual Growth Rate)

NVIDIA's revenue surged from $39.3 billion in one quarter to $57.0 billion just three quarters later — a pace that, annualized, represents roughly 56% compound growth. Apple, meanwhile, grew its trailing twelve-month revenue from $395.8 billion to $435.7 billion over the same period, a steadier but still impressive 10.1%. How do you compare two such different growth trajectories on equal footing? The answer is CAGR — Compound Annual Growth Rate. CAGR is one of the most widely used metrics in finance, appearing in earnings calls, analyst reports, investment prospectuses, and stock screeners. It smooths out the noise of quarterly volatility to give you a single annualized growth rate that captures how an investment or business metric evolved over time. Whether you're evaluating a stock, comparing mutual fund performance, or sizing up an entire economy's expansion, CAGR is the tool that puts everything on the same playing field. Despite its ubiquity, CAGR is often misunderstood. It's not the same as an average return. It doesn't tell you anything about the path taken between the start and end dates. And it can be dangerously misleading if applied to the wrong time frame. This guide breaks down exactly what CAGR measures, how to calculate it, and — just as importantly — when not to rely on it.

CAGRcompound annual growth rateinvestment returns

XOM: ExxonMobil's $621 Billion Energy Empire Rallies 50%

Exxon Mobil Corporation (NYSE: XOM) has staged one of the most impressive rallies in the energy sector, surging roughly 50% from its May 2025 low of $97.80 to trade at $147.28 as of February 21, 2026. The world's largest publicly traded oil company now commands a market capitalisation of $621 billion, making it the undisputed heavyweight of Western energy. With 43 consecutive years of dividend increases and $52 billion in annual operating cash flow, ExxonMobil remains a cornerstone holding for income-focused investors. Yet the headline numbers mask a more nuanced picture. Fourth-quarter 2025 results revealed meaningful margin compression, with operating income dropping to 7.5% of revenue — roughly half the rate posted in Q1. Full-year net income fell to $28.8 billion from $33.7 billion in 2024, while free cash flow declined to $23.6 billion from $30.7 billion. At 22 times trailing earnings, XOM is no longer the deep-value play it was nine months ago. The question for investors is whether the company's production growth, carbon capture investments, and capital discipline can justify a premium multiple in a normalising energy market.

XOMExxonMobilstock analysis

PEP: PepsiCo's $226 Billion Snack-and-Sip Empire Rallies

PepsiCo (NASDAQ: PEP) has staged a remarkable recovery. After plunging to a 52-week low of $127.60 amid consumer spending worries and volume declines across its Frito-Lay division, the stock has surged 29% to trade at $164.94 — within 4% of its 52-week high of $171.48. The $226 billion beverage and snack food giant just reported fiscal 2025 results, and the picture is more nuanced than the rally suggests. Full-year revenue came in at roughly $93.9 billion across four quarters, with diluted EPS of $6.00. The company generated $12.1 billion in operating cash flow and $7.7 billion in free cash flow — numbers that underpin PepsiCo's status as a Dividend King with 54 consecutive annual dividend increases. At 27.5x trailing earnings, the stock commands a premium that demands scrutiny. The question for investors now is straightforward: after a 29% run, does PepsiCo still offer value, or has the easy money been made? With a new 10% global tariff regime taking shape and PepsiCo's significant international exposure, the answer depends on whether this cash flow machine can sustain its dividend growth while navigating rising input costs and shifting consumer preferences.

PepsiCoPEP stockDividend King

NKE: Nike's $97 Billion Turnaround Under New CEO Elliott

Nike, Inc. (NYSE: NKE) is at an inflection point. The world's largest athletic footwear and apparel company trades at $65.40 — down 21% from its 52-week high of $82.44, though up 25% from the $52.28 low it touched in 2025. The stock's $97 billion market capitalization still dwarfs every competitor, but the narrative has shifted dramatically from the days when Nike commanded a premium multiple as the undisputed king of global sportswear. New CEO Elliott Hill, who took the reins after a decades-long career inside Nike, has acknowledged the problems: over-reliance on a few legacy franchises, a botched direct-to-consumer pivot that alienated wholesale partners, and margin erosion from markdowns. His turnaround plan centres on relaunching performance innovation — including the ACG outdoor brand unveiled in Milan this week — rebuilding wholesale relationships, and cutting costs. The market is cautiously optimistic, pricing the stock at 38x trailing earnings while waiting for proof that the strategy is working. The February 19 CNBC report that New Balance's 2025 sales surged 19% to $9.2 billion underscores the competitive pressure Nike faces. Add Trump's new 10% global tariff — which directly impacts Nike's Asia-heavy supply chain — and the turnaround task becomes even more daunting. Yet Nike's scale, brand power, and $8.3 billion cash position give it resources that no competitor can match. The question is whether Hill can deploy them fast enough.

NikeNKEstock analysis

MA Analysis: Mastercard's $470 Billion Payments Empire

Mastercard Incorporated (NYSE: MA) trades at $526.41, roughly 12.5% below its 52-week high of $601.77 — a discount that feels unusual for a company generating 46% net margins and $16.9 billion in annual free cash flow. The payments giant reported full-year 2025 revenue of $32.8 billion, capping a year in which every quarter delivered accelerating growth. Q4 net income hit $4.06 billion, or $4.52 per diluted share, as operating margins expanded above 61%. Yet the stock has drifted lower from its peaks, dragged by broader fintech rotation and concerns about whether a 31.8x trailing PE can be justified when growth is decelerating from mid-teens toward low double digits. The 50-day moving average sits at $553, meaning shares are trading nearly 5% below that level — a technical signal that momentum has clearly shifted. For long-term investors, the question is straightforward: does Mastercard's unmatched network economics, consistent capital return, and secular digital payments tailwind justify holding through the drawdown — or has the premium finally stretched too far? The data points toward the former, but the margin of safety is thinner than it has been in years.

MastercardMA stockpayment networks

Amazon Dethrones Walmart as the World's Largest Company by

For decades, Walmart held an unchallenged claim to the title of the world's largest company by annual revenue. That era ended this week. Amazon's full-year 2025 revenue of $716.9 billion officially surpassed Walmart's $713.2 billion for its fiscal year ending January 31, 2026 — a symbolic but seismic milestone that reshapes the hierarchy of global commerce. The dethroning was not sudden. Amazon first overtook Walmart in quarterly revenue about a year ago, and the annual crossover had been anticipated for months. But the confirmation, arriving just as Walmart reported otherwise strong fourth-quarter results on Thursday, crystallizes a broader truth: the center of gravity in retail has shifted decisively toward digital platforms, cloud computing, and AI-powered commerce. For investors parsing the two stocks — Amazon trading at $209.44 with a $2.25 trillion market cap, and Walmart at $122.07 with a $973 billion valuation — the question is no longer who is bigger, but which company is better positioned for the next chapter. The milestone also arrives at a pivotal moment for both companies. Amazon is pouring up to $200 billion into AI infrastructure in 2026, while Walmart is navigating a CEO transition and a cautious earnings outlook that spooked Wall Street. The revenue crown may be symbolic, but the strategic divergence underneath it is anything but.

AmazonWalmartrevenue milestone

JNJ Analysis: At a 52-Week High and Reshaping Its Portfolio

Johnson & Johnson is trading at $246.61, within touching distance of its 52-week high of $246.88 and a staggering 74% above its 52-week low of $141.50. That kind of run from a $594 billion healthcare giant isn't supposed to happen — and yet here we are, watching one of the most defensive names in the market act like a growth stock. The catalyst isn't a single product launch or earnings beat. It's a wholesale reshaping of what JNJ actually is. Today's news that the company is exploring a $20 billion sale of its orthopedics unit, combined with a $1 billion investment in cell therapy manufacturing in Pennsylvania, tells you everything about where management is taking this business: away from commoditized medical devices and toward the high-margin frontier of biologics and cell-based therapies. For investors who bought the Kenvue spinoff dip below $150, the returns have been exceptional. The question now is whether JNJ at 22x earnings still offers value, or whether the portfolio transformation is already priced in.

Johnson & JohnsonJNJstock analysis